Philanthropy and trusts

Individual philanthropists and grant-making trusts and foundations play a pivotal role in funding our vital work.

We need your generous support so that we can continue to fight pancreatic cancer on all fronts; through investing in cutting-edge research, providing specialist support and information, and campaigning for change.

Get in touch

If you’re considering a gift of £5,000 or more, thank you. You’ll be joining a dedicated community helping to transform the future for people affected by pancreatic cancer.

Our dedicated philanthropy team will work closely with you to ensure your gift reflects what matters most to you, from funding bold new research and speeding up diagnosis to supporting patients and families with expert care and information. You’ll receive personalised updates on the impact of your support, and opportunities to connect more deeply with the work you’re helping to make possible.

To find out more about making a major gift, please contact:

Sabina Pasokhy
Philanthropy Lead 
Email: Sabina.Pasokhy@pancreaticcancer.org.uk

What do we mean by a significant gift?

At Pancreatic Cancer UK we are extremely grateful for each and every donation we receive. We define donations of over £5,000 as a significant gift.

Make us your beneficiary charity of choice

If you’re holding an event and would like to support a charity, we would love to work with you to make your event as special as possible. 

Find out more
  • Just 12% of pancreatic cancer patients given the chance to join a clinical trial

    Just 12% of pancreatic cancer patients given the chance to join a clinical trial

    Only 12% of people with pancreatic cancer are given the chance to take part in a clinical trial, emphasising the lack of progress in developing treatm...

  • We’re demanding treatment breakthroughs. We’re demanding survival.

    We’re demanding treatment breakthroughs. We’re demanding survival.

    Today marks the launch of our Demand Survival Now petition, calling on governments across the UK to fund more research for treatment breakthroughs

  • Our response to the daraxonrasib clinical study and KRAS inhibitors

    Our response to the daraxonrasib clinical study and KRAS inhibitors

    Our comment on daraxonrasib results and the promising group of therapies known as KRAS inhibitors.